/NGNE
NGNE Stock - Neurogene Inc.
Healthcare|BiotechnologyNASDAQ
$20.55+6.59%
+$1.27 (+6.59%) • Dec 19
67
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.43
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.55
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+119.0%upside
Target: $45.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NGNE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$20.34 – $20.76
TARGET (TP)$45.00
STOP LOSS$18.91
RISK/REWARD1:14.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.63
52W High$37.27
52W Low$6.88
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $925,000 | N/A | N/A | N/A | N/A |
| Gross Profit | $-2,322,000 | $-3,262,000 | $-3,196,000 | $-42,264,000 | $-1,821,000 |
| Gross Margin | -251.0% | N/A | N/A | N/A | N/A |
| Operating Income | $-82,605,000 | $-55,583,000 | $-56,517,000 | $-50,534,000 | $-41,554,000 |
| Net Income | $-75,144,000 | $-36,317,000 | $-55,189,000 | $-50,517,000 | $-33,277,000 |
| Net Margin | -8123.7% | N/A | N/A | N/A | N/A |
| EPS | $-4.28 | $-2.83 | $-4.30 | $-0.92 | $-0.64 |
Company Overview
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
8
89%
Hold / Neutral
1
11%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
8 Bullish1 Neutral/Bearish
Price Targets
$47
Average Target
↑ 128.7% Upside
Now
$24
Low
$47
Average
$65
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 17th 2025 | Craig Hallum | Initiation | Buy | $50 |
| May 16th 2025 | Robert W. Baird | Downgrade | Neutral | $24 |
| June 27th 2024 | BMO Capital Markets | Initiation | Outperform | $65 |
| June 11th 2024 | Robert W. Baird | Initiation | Outperform | $54 |
| April 29th 2024 | Leerink Partners | Initiation | Outperform | $46 |
| March 21st 2024 | William Blair | Initiation | Outperform | $61 |
| January 8th 2024 | H.C. Wainwright | Initiation | Buy | $45 |
| January 5th 2024 | Stifel | Initiation | Buy | $31 |
| January 4th 2024 | TD Cowen | Initiation | Outperform | - |
Earnings History & Surprises
NGNEBeat Rate
80%
Last 15 quarters
Avg Surprise
+37.3%
EPS vs Estimate
Beats / Misses
12/3
Last 12 quarters
Latest EPS
$-0.99
Q4 2025
EPS Surprise History
Q1 24
-29.1%
$-1.51vs$-1.17
Q2 24
+2.9%
$-1.00vs$-1.03
Q3 24
-6.9%
$-1.09vs$-1.02
Q4 24
+2.5%
$-1.19vs$-1.22
Q1 25
+4.8%
$-0.99vs$-1.04
Q2 25
-2.9%
$-1.08vs$-1.05
Q3 25
+8.7%
$-1.05vs$-1.15
Q4 25
+21.4%
$-0.99vs$-1.26
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 23, 2026 | $-1.20 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-1.26 | $-0.99 | +21.4% | ✓ BEAT |
Q3 2025 | Aug 11, 2025 | $-1.15 | $-1.05 | +8.7% | ✓ BEAT |
Q2 2025 | May 9, 2025 | $-1.05 | $-1.08 | -2.9% | ✗ MISS |
Q1 2025 | Mar 24, 2025 | $-1.04 | $-0.99 | +4.8% | ✓ BEAT |
Q4 2024 | Nov 18, 2024 | $-1.22 | $-1.19 | +2.5% | ✓ BEAT |
Q3 2024 | Aug 9, 2024 | $-1.02 | $-1.09 | -6.9% | ✗ MISS |
Q2 2024 | May 10, 2024 | $-1.03 | $-1.00 | +2.9% | ✓ BEAT |
Q1 2024 | Mar 26, 2024 | $-1.17 | $-1.51 | -29.1% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-0.80 | $-0.41 | +48.8% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.15 | $-0.04 | +73.3% | ✓ BEAT |
Q1 2023 | Mar 30, 2023 | $-4.40 | $-0.26 | +94.2% | ✓ BEAT |
Q4 2022 | Dec 30, 2022 | $-3.80 | $-0.32 | +91.7% | ✓ BEAT |
Q3 2022 | Sep 30, 2022 | $-6.09 | $-2.36 | +61.2% | ✓ BEAT |
Q2 2022 | Jun 29, 2022 | $-6.00 | $-0.28 | +95.3% | ✓ BEAT |
Q1 2022 | Mar 31, 2022 | — | $-0.28 | — | — |
Q4 2021 | Dec 30, 2021 | $-5.96 | $-0.36 | +94.0% | ✓ BEAT |
Q3 2021 | Sep 29, 2021 | — | $-0.28 | — | — |
Q2 2021 | Jun 29, 2021 | — | $-0.27 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.27 | — | — |
Latest News
Neurogene Q3 EPS $(0.99) Beats $(1.25) Estimate
📈 PositiveBenzinga•Nov 13, 2025, 10:26 PM
HC Wainwright & Co. Maintains Buy on Neurogene, Raises Price Target to $70
📈 PositiveBenzinga•Nov 13, 2025, 12:44 PM
Neurogene Announces Updated Interim Clinical Study In Pediatric Group From Its Current Phase 1/2 Trial Evaluating NGN-401 Demonstrates All 8 Patients Showed Functional Gains Across Spectrum Of Disease Severity
📈 PositiveBenzinga•Nov 12, 2025, 09:13 PM•Also:
Neurogene Doses First Participant In Its Embolden Registrational Trial Of NGN-401 Gene Therapy For Rett Syndrome
📈 PositiveBenzinga•Nov 6, 2025, 12:35 PM
HC Wainwright & Co. Maintains Buy on Neurogene, Raises Price Target to $65
📈 PositiveBenzinga•Oct 31, 2025, 10:58 AM
Neurogene shares are trading higher after the company announced it completed discussions with the FDA on the Embolden trial, and it plans to initiate dosing in Q4 2025 across 13 Rett syndrome sites.
📈 PositiveBenzinga•Oct 9, 2025, 03:59 PM
HC Wainwright & Co. Reiterates Buy on Neurogene, Maintains $45 Price Target
📈 PositiveBenzinga•Oct 9, 2025, 02:32 PM
Neurogene Completes Discussions With FDA On Embolden Trial, Plans To Initiate Dosing In Q4 2025 Across 13 Rett Syndrome Sites
📈 PositiveBenzinga•Oct 9, 2025, 11:08 AM
Neurogene downgraded to Neutral at Baird on regulatory uncertainty
📉 NegativeSeeking Alpha•May 16, 2025, 03:18 PM
Frequently Asked Questions about NGNE
What is NGNE's current stock price?
Neurogene Inc. (NGNE) is currently trading at $20.55 per share. The stock has moved +6.59% today.
What is the analyst price target for NGNE?
The average analyst price target for NGNE is $45.00, based on 1 analyst.
What sector is Neurogene Inc. in?
Neurogene Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is NGNE's market cap?
Neurogene Inc. has a market capitalization of $0.32 billion, making it a small-cap company.
Does NGNE pay dividends?
No, Neurogene Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADCT
ADC Therapeutics S.A.
$3.73
Mkt Cap: $0.4B
ALMS
Alumis Inc. Common Stock
$11.29
Mkt Cap: $1.2B
AUTL
Autolus Therapeutics plc
$1.63
Mkt Cap: $0.4B
BNTC
Benitec Biopharma Inc.
$11.50
Mkt Cap: $0.3B
FULC
Fulcrum Therapeutics, Inc.
$12.28
Mkt Cap: $0.7B
LCTX
Lineage Cell Therapeutics, Inc.
$1.68
Mkt Cap: $0.4B
OCGN
Ocugen, Inc.
$1.40
Mkt Cap: $0.4B
PRTC
PureTech Health plc
$16.78
Mkt Cap: $0.4B
QSI
Quantum-Si incorporated
$1.27
Mkt Cap: $0.2B
SLDB
Solid Biosciences Inc.
$5.94
Mkt Cap: $0.5B
Explore stocks similar to NGNE for comparison